Vixa Skineal

Manufacturer
Yunnan Yuyao Bio-pharmaceutical Co.,Ltd.
Effective date
2025-02-05
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
2
Source
full-release
Hydrated at
2026-05-31 21:25:10

Label at a glance#

ProductVixa Skineal
Active ingredientCLOBETASOL PROPIONATE, NEOMYCIN SULFATE, KETOCONAZOLE
Label structure2 sections

Label contents#

Full prescribing information#

DOSAGE & ADMINISTRATION SECTION

DOSAGE AND ADMINISTRATION:
Apply externally to affected area twice daily. It is suggested to use for 2 weeks on ordinary tinea corporis and tinea cruris, for 4 weeks on tinea pedis and tinea manus.
SIDE EFFECTS:
VIXA SKINEAL has few side effects when used topically. A few instance of irritation or burning sensation may be observed occasionally during the treatment. But usually, it is unnecessary to stop the drug.
CONTRAINDICATION:

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

LabelingLabelingDESCRIPTION:
A white or off-white cream with emulsive base.
PHARMACOLOGICAL ACTIONS:
Ketoconazole is a broad-spectrum anti-fungal agent that acts on the cell membranes of fungi by changing its permeability. Pharmacological studies have shown that Ketoconazole has extremely potent antimycotic actions against dermatophytes (such as Trichophyton sp., Microsporum sp., and epidermophyton sp.), saccharomyces and candida albicans. Strains of fungi are unlikely to have a natural resistance to Ketoconazole. Clobetasol Propionate is cortex hormone that is highly effective as an anti-inflammatory and anti-allergic agent with a few side effects. Neomycin Sulfate is effective against Gram-positive cocci and Gram-negative bacilli. As a result, this compound cream is jointly effective against fungus, bacteria, inflammation and pruritus.
INDICATIONS:
VIXA SKINEAL is indicated for topical application on the treatment of fungal infection of skin, such as tinea manus, tinea pedis, tinea corporis, tinea cruris and tinea versicolor. It is also proved effective on the treatment of many kinds of dermatitis, eczema and pruritus.
DOSAGE AND ADMINISTRATION:
Apply externally to affected area twice daily. It is suggested to use for 2 weeks on ordinary tinea corporis and tinea cruris, for 4 weeks on tinea pedis and tinea manus.
SIDE EFFECTS:
VIXA SKINEAL has few side effects when used topically. A few instance of irritation or burning sensation may be observed occasionally during the treatment. But usually, it is unnecessary to stop the drug.
CONTRAINDICATION:
VIXA SKINEAL is contraindicated in patients with known hypersensitivity to any of its ingredients. It is not for ophthalmic use. Take special precautions when using on pregnancy and infancy.
PRECAUTIONS:
It should be under doctor's supervision to apply VIXA SKINEAL on the face or on large areas for a long period of time.
PACKAGE:
Each tube contains 15g.
STORAGE:
STORE IN A DRY PLACE BELOW 30°C AND AWAY FROM THE SUNLIGHT.
EXPIRATION DATE:
Three years after the manufacturing date.
FOR EXTERNAL USE ONLY. KEEP OUT OF REACH OF CHILDREN. AVOID CONTACTING EYES.
READ PACKAGE INSERT CAREFULLY BEFORE USING. BATCH NO., MFG. DATE, EXP. DATE ON BOX CAP.
Mfg. by: Yunnan Yuyao Bio-Pharmaceutical Co., Ltd.
Address: High & New Technology Industries Development Zone, Yuxi City, Yunnan Province, P.R.China.

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
CLOBETASOL Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813
KETOCONAZOLE Pharmacologic Class Indexing3Indexing - Pharmacologic Class20180813
NEOMYCIN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
fd9dd88b-5db8-6370-b47e-37f6c9b1c5d5Product name220250331
20abe2c3-3e80-d2b2-39eb-3156e4af4799Product name320250124
45ad92f8-d116-4c0c-851c-2e740b7d8e6fProduct name120250122
42be0ad5-6fd7-4f1b-8108-6d9dd7d571dfProduct name720250107
3813b789-94b9-edd6-f010-6b926dd462e5Product name520230113
30eee8a1-850e-41ed-b5ab-761301aeab49Product name620221206
1e18fb2e-aeff-8efe-93be-5a5f7be8faa2Product name220211209
8bc3781f-20ed-678b-44a7-a981e693c65fProduct name220211209
18e5b6f7-c414-b1f1-b684-17fdd02c215eProduct name420210927
1c87bbde-dd91-a122-db33-67ae814cb645Product name720210510
519b5875-7d7d-4aa6-9d3d-470fa1376595Product name420200227
ff3a8c91-648c-300b-467e-10703f514265Product name220180809
98669154-3e9c-47da-8a2c-656ab71848beProduct name220180607
8d4f8539-436f-453b-8b76-5322d403fc8eProduct name120180131
837ac3c6-ee71-c5a6-6eba-c4065f37e9f5Product name220171010
99e684e6-f435-feb8-d2bb-3a546f1cb768Product name220161117
152a96a4-36b6-f5b1-d4e6-9a500e06bbf3Product name120140508
b045ad64-0f28-9a02-2f9b-b34d94fb2278Product name120140508
b6082387-f592-1148-0844-bd068fd213fbProduct name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
84659-9040-1Vixa Skineal15 g in 1 BOXCREAM152

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
84659-9040VIXA SKINEAL (VIXA SKINEAL COMPOUND KETOCONAZOLE) CREAM [YUNNAN YUYAO BIO-PHARMACEUTICAL CO.,LTD.]21 package rows20250207_1fa97d48-bd20-ce34-e063-6394a90adb1c.zip

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 7 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
84659-904084659-9040-1

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 3 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
2d6ab2de-0d12-38c5-e063-6394a90ac9431fa97d48-bd20-ce34-e063-6394a90adb1c2025-02-05Exact identifier
spl id: 2d6ab2de-0d12-38c5-e063-6394a90ac943
spl set id: 1fa97d48-bd20-ce34-e063-6394a90adb1c

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.